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1. Introduction 
Chagas disease is a systemic parasitic infection caused by the protozoan Trypanosoma cruzi, 
which persists as an important public health problem, mainly in Latin America where 
triatomine vectors are located in three overlapping cycles of transmission: domestic, 
peridomestic, and sylvatic. Due to human migration from endemic to developed countries, in 
recent years Chagas disease has become a recognized global problem. This chapter reviews 
current literature on chagasic cardiomyopathy, its etiology, epidemiology, immunology, and 
diagnosis, along with etiologic and symptomatic treatment and prognosis. 
2. Etiology 
One-hundred years after the discovery of Trypanosoma cruzi (Family: Trypanosomatidae, 
Order: Kinetoplastida) by Carlos Chagas in Brazil, many aspects of its biology and host 
relationship remain unraveled. The substantial biological, biochemical, and genetic 
variability of this parasite, as well as the multiclonal T. cruzi infection character are some of 
the factors that have hampered its study. T. cruzi is considered to have a clonal structure 
with some overlapping events of genetic exchange occurring in the past that have brought 
about the six currently recognized Discrete Typing Units (DTUs) I to VI. Moreover, within 
each DTU biological and genetic polymorphism is present, especially in DTUs I and III. The 
scenario is even more complicated. Recent reports showed that multiple genotypes were 
obtained when isolates from a single wild mammalian reservoir host were cloned (Llewelyn 
et al., 2011). The authors proposed that this huge diversity is at least, partially driven by the 
survival in the host. Nonetheless, significant progress has been achieved with the unveiled 
T. cruzi genome and the following OMICS initiatives such as RNAomic and proteomic 
analyses, which seek to apply translational medicine to Chagas disease in the near future.  
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2.1 Life cycle 
T. cruzi exhibits a complex life cycle involving four well-defined developmental stages that 
interplay into two hosts, the blood-sucking insect vector, and the mammalian host (humans 
and animals). After already-infected insects feed on the mammalian host, they eliminate in 
their feces the metacyclic trypomastigotes (parasite infective form), which penetrate the 
body through the bite-wound, any damaged tissue, or the mucosa from eyes, nose, or even 
the digestive tract and invade host cells like fibroblasts, macrophages, and epithelial cells at 
the inoculation site. In the cytoplasm, free-parasites are differentiated into amastigotes 
(Fig.1A), the intracellular stage, which after several replication rounds transforms back into 
trypomastigotes that rupture the host membrane cell, infecting new cells or disseminating 
into other organs via the bloodstream.  
 
   
A B C 
Fig. 1. (A) Intracellular amastigotes of T. cruzi-infecting Vero cells, (B) Trypomastigotes, and 
(C) Epimastigotes stained with Giemsa. Courtesy of Paola Lasso, and Paula Pavia, 
Laboratory of Molecular Parasitology, School of Sciences, Pontificia Universidad Javeriana, 
Bogota D.C., Colombia. 
Upon feeding, insects take the bloodstream trypomastigotes (Fig. 1B), which once in their 
digestive tract differentiate into epimastigotes, the insect replication stage (Fig. 1C). After 
reaching the rectum, parasites transform into metacyclic trypomastigotes ready to infect a 
new mammalian host. From this cycle, it is obvious that the differential expression of 
parasite genes enable the parasite to accomplish the role played by each of its 
developmental stages. In this sense, several proteomic studies have been performed to 
identify molecules participating in cycle-vital processes (Ulrich et al., 2011). 
3. Epidemiology and risk factors 
3.1 Burden of Chagas disease 
An estimated 10-million people are infected worldwide, mostly in Latin America where 
Chagas disease is endemic. More than 25-million people are at risk of contracting the disease. 
It is estimated that in 2008 Chagas disease killed >10,000 people. With a latency of 10-30 years, 
nearly 30% of infected patients develop life-threatening complications, mostly Chagas heart 
disease (CHD) (WHO, 2010). Direct and indirect costs of T. cruzi infection impose an 
overwhelming load on healthcare systems secondary to hospitalizations and medical and 
surgical treatments for CHD, gastrointestinal dysfunction, and meningoencephalitis in Latin 
America (Franco-Paredes et al., 2007). In 1995, the burden of Chagas disease in Latin America 
was estimated at US$8.156-billion, equivalent to 2.5% of the foreign debt of continental Latin 
America (Moncayo, 2003). More recent data demonstrate that, globally, Chagas disease is 
associated with 0.7-million disability-adjusted life years, constituting the sixth most important 
neglected tropical disease worldwide (Hotez et al., 2006).  
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3.2 Globalization of Chagas disease 
Political and economic situations have stimulated the flow of migration from the 17 Latin 
American endemic countries to the developed ones (Schmunis  & Yadon, 2010). Because of this 
and parasite transfer by blood contact, intrauterine transfer, laboratory accidents, and organ 
transplantation; CHD could potentially become a worldwide problem (WHO, 2010) and 
emerge as a public health issue in non-endemic countries (Field et al., 2010). Currently, in the 
United States it is estimated that from more than 22 million of immigrants from endemic 
countries there are approximately 300,000 infected individuals (Bern & Montgomery, 2009). In 
15 European countries in 2005, excluding Spain, 2.9% of the 483,074 legal Latin American 
immigrants were estimated to be infected with T. cruzi. By 2008, Spain had received 1,678,711 
immigrants from Latin American endemic countries; of these, 5.2% were potentially infected 
with T. cruzi and 17,390 may develop Chagas disease. Likewise, in an analysis of Chagas 
disease in Spain, most patients were from Bolivia (94.7%) and less from Brazil, Chile, Ecuador, 
Paraguay, and Honduras (Norman et al., 2010). Other countries outside Europe, where the 
rates of Latin American immigration are high and present an important prevalence of Chagas 
disease are Australia, Canada, and Japan (Schmunis & Yadon, 2010). 
3.3 Chagas heart disease in endemic countries 
Triatomines, the T. cruzi vectors, are spread from the south of the United States to the south of 
Argentina. The rarity of vector-borne transmission in the United States, compared with Latin 
America, is thought to be the result of better housing conditions and lower efficiency of North 
American vectors (Bern & Montgomery, 2009). In Latin America, there are more than 125 
potential vectors of Chagas disease. However, species with higher vectorial capacity, with 
domestic habits and with the most geographical distribution belong to Triatoma, Rhodnius, and 
Panstrongylus genera. For these reasons, there are different targets in control programs of 
vectors depending on regions. Thus, the Mexico and Central America Initiative (created in 
1998) is focused in the control Rhodnius prolixus, Triatoma dimidiata, Triatoma barberi, and 
Rhodnius pallescences; the Initiative of the Andean Countries (created in 1997) is aimed at 
controlling R. prolixus, T. dimidiata and Triatoma maculata; and finally, the Initiative of the 
Southern Cone (created in 1991) is aimed at controlling Triatoma infestans, Triatoma brasiliensis, 
Triatoma sordida, and Panstrongylus megistus (Guhl, 2009). The main risk factors for vector-
borne transmission are related to previous exposure to poor housing conditions in Latin 
America (Fig. 3), such as: palm or straw roofs, dirt floors, adobe walls or walls with low 
quality or incomplete plastering, and the presence of animals inside the bedroom. 
 
 
Fig. 2. Typical house in a Chagas disease endemic region, Departamento de Boyacá. 
Courtesy of Cielo León, Grupo de Parasitología, Instituto Nacional de Salud, Colombia.  
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An important change has occurred in trends of Chagas disease in Latin America over recent 
decades. Such is recognized by several researchers, control policies of vector and blood of T. 
cruzi transmission have shown a positive effect in reducing the incidence of this disease. 
Thus, since the 1990s until now, an important success in the control of Chagas disease has 
been observed, especially in Southern Cone countries. So, in 1990, the distribution of Chagas 
disease in 21 countries was estimated, with more than 45,000 deaths per year and 30-million 
cases of human infection; while in 2006 the distribution of Chagas disease in 18 countries 
was estimated, with approximately 12,500 deaths per year and nearly 15-million cases of 
human infection (Dias et al., 2008). Success in controlling vector transmission in some 
countries has led to also to focus the attention to other forms of non-vector transmission. 
Thereby, controlling transmission by transfusion has improved and screening is now 
obligatory in most endemic countries. Congenital transmission has been detected as an 
important transmission form, mainly in Bolivia, but other endemic countries have only 
recently started to approach to this problem. Orally acquired human infection with T. cruzi 
has been known since the 1930s but has the interest in this transmision has increased as a 
result of the series of outbreaks that have occurred in the Amazon region, which have been 
associated with the preparation and consumption of some foods, especially in Brazil, 
Venezuela, and Colombia (Miles, 2010). The rural-to-urban migration movements that have 
occurred in Latin America since the 1970s and 1980s have changed the traditional 
epidemiological pattern of Chagas disease as a rural condition and transformed it into an 
urban infection that can be transmitted via non-vector manners (Moncayo & Silveira, 2009). 
Moreover, in some countries the vector infestation has occurred in urban areas where 
vectors have been introduced by passive transportation during migration process, for 
instance in Cochabamba, Bolivia (Medrano-Mercado et al., 2008), Arequipa, Peru (Bayer et 
al., 2009), and in Yucatán, Mexico (Guzman-Tapia et al., 2007). On the other hand, adults 
infected with T. cruzi from childhood form a transitional generation, experiencing the 
simultaneous impact of past infectious exposures and current cardiovascular risk factors, 
such as sedentary lifestyle, calorie-dense diets, hypertension, and diabetes. Other variables 
such as longer residence in an endemic province, residence in a rural area and poor housing 
conditions, male sex, and increased age have been found independent predictors of Chagas 
cardiomyopathy severity (Hidron et al., 2010).  
3.4 Surveillance and health policy 
In endemic countries, the tools to interrupt the domestic cycle of T. cruzi transmission, such 
as chemical control, housing improvement, and health education are the most useful 
methods to prevent Chagas disease (Moncayo & Silveira, 2009). Blood screening is vital to 
prevent infection through transfusion and organ transplantation and governments should 
implement policies to promote it (WHO, 2010). In addition, an infrastructure that assures 
detection and treatment of acute and chronic cases, as well as congenital infection should be 
developed. In non-endemic countries, screening programs in Latin American pregnant 
women are increasing and it has been proposed that in some non-endemic countries there is 
cost-effectiveness to develop it (Sicuri et al., 2011). Regarding strategies to reduce 
transmission by transfusion in non-endemic countries, there are two different approaches: 
one is the deferral of individuals at risk of Chagas disease and the second approach is to 
accept blood donations if specific laboratory assays are negative. This second approach is 
being introduced in countries where there is a substantial Latin American population, such 
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as the United States, Spain, and France (Castro, 2009). Also, taking into account that 
knowledge about Chagas disease among doctors in non-endemic countries is very limited 
(Verani et al., 2010), strategies to improve awareness are very important in order to enhance 
treatment and follow up of cases. 
4. Clinical presentation  
4.1 Acute phase 
The symptomatic acute phase could be present at any age but it is most common in children 
under 10 years of age. When the infection is acquired via vector, it takes four to eight weeks 
for symptoms to develop. In this phase there is an important inflammatory response in the 
site of contact with bug feces and T. cruzi may multiply locally (cutaneous chagoma when it 
is in the skin). The insect prefers the thinnest skin and that is why the best known sign is 
Romaña’s sign which consists in a unilateral conjunctivitis with periorbital edema, eyelid 
edema and pre-auricular adenopathy (Biolo et al., 2010). In younger children (under 4 years 
of age) it is common to found the following symptoms: fever, malaise, muscle pain, 
anorexia, anemia, sweating, hepatosplenomegaly, heart failure from myocarditis, pericardial 
effusion, seizures, and somnolence secondary to meningoencephalitis, the more infrequent 
form of presentation (Gomez et al., 2007). The acute congenital disease should be considered 
by the medical care system staff in endemic areas; it could be asymptomatic or may be 
associated to prematurity, low weight, hepatomegaly, splenomegaly, jaundice, anemia, 
neonatal hepatitis, meningoencephalitis, sepsis, myocarditis, fever, and less frequently 
megaesophagus, megacolon, megabladder. Without treatment, mortality is 5-10%, the 
leading causes are encephalomyelitis and heart failure (Prata, 2001). Patients with HIV could 
reactivate the disease and have meningoencephalitis as a first manifestation (Carod-Artal, 
2006). In patients with history of solid organ or bone marrow transplants, 30% reactivate 
Chagas disease, the acute manifestations could be myocarditis, panniculitis, subcutaneous 
parasite-containing nodules, and meningoencephalitis (Bern et al., 2007).  
4.2 Chronic phase 
Once the acute phase is resolved, it begins the chronic phase. This chronic phase could be 
asymptomatic lifelong or progressive heart and/or gastro esophageal disease. The chronic 
asymptomatic or indeterminate phase lasts 10 to 30 years. For some authors its definition 
means epidemiological contact, positive serologic tests, normal physical examination and 
normal radiological, electrocardiographic and echocardiography studies. Around 30% of 
these have progressive disease (Higuchi et al., 2003). When Chagas becomes symptomatic, 
depending on the geographic zone, the disease will have different signs and symptoms. In 
Central America and northern South America, the heart disease is the common 
manifestation, but in Brazil and Southern Cone countries it coexists with digestive 
syndromes (Miles et al., 2003). For the purpose of this review, we will focus on Chagasic 
cardiomyopathy. The earliest manifestations of heart disease are electrocardiographic 
abnormalities as the expression of the damage of the conduction system and the symptoms 
that the patients experience could be related to those abnormalities: atrioventricular block, 
sinus bradycardia, premature ventricular contractions, atrial fibrillation, and ventricular 
tachycardia. In 40% of patients with mild heart disease there could be non-sustained 
ventricular tachycardia, as well as in 90% of patients with heart failure. Sudden death occurs 
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in 38% of patients with chronic disease with or without heart failure, meaning more severe 
heart disease. The principal cause of sudden death is the malignant ventricular arrhythmia 
followed by advanced atrioventricular block and cerebral emboli. Non-sustained ventricular 
tachycardia in Holter monitoring and in stress test, together with low ejection fraction, 
syncope and pre-syncope, sinus node dysfunction, history of recovery from cardiac arrest, 
and dyspnea NYHA class III or IV have been recognized of prognostic value in sudden 
death (Prata, 2001). Symptomatic heart failure occurs in some patients before there is any 
significant electrocardiography alteration. It could be right or left heart failure; it is very 
common for patients to have severe structural heart disease and not show symptoms of 
severe heart failure. It is also common to find severe congestive hepatic disease. Pulmonary 
and systemic emboli due to dilated chambers of apical aneurism are common clinical 
manifestations of chronic heart disease (Bern et al., 2007); they have been described in 40% 
of autopsies (Prata, 2001). A Brazilian study found four predictors of emboli complications: 
age > 48 years, primary changes in repolarization, apical aneurism, and ejection fraction < 
50%, with a 4% annual incidence if all four factors where present (Sousa et al., 2008). 
Precordial pain is a frequent complaint of patients with Chagas disease. The incidence of 
this symptom is 15% but other authors report up to 30% (Marin-Neto et al., 2007). The 
causes of the symptom are not clear; some authors believe that this pain could be caused by 
microvascular disease.  
4.2.1 Classification 
A simple classification, published by the Brazilian Consensus on Chagas Diseases, includes 
functional capacity, electrocardiographic findings, function and size of left ventricle. This 
classification allowed defining four disease stages with the aim to orientate the patient’s 
therapy (Table 1). 
 
Stage Electrocardiogram Echocardiography Heart failure 
A Altered Normal Absent 
B1 Altered Altered LVEF >45% Absent 
B2 Altered Altered LVEF <45% Absent 
C Altered Altered Compensated 
D Altered Altered Refractory 
LVEF: left ventricular ejection fraction 
Table 1. Classification of cardiac compromise in Chagas chronic cardiomyopathy  
5. Pathogenesis of cardiac disease during T. cruzi infection 
5.1 Host genetic influence 
Some works approach the influence of human genetics such as Histocompability Complex 
Molecules (HLA) or polymorphism in cytokine promoters and their contribution to Chagas 
disease. So far, association with HLA class II indicated that infected individuals with and 
without cardiomyopathy had a higher frequency of DRB1*01, DRB1*08, and DQB1*0501 
(Fernandez et al., 1998), and the DRB1*01 DQB1*0501 haplotype was more frequent in 
patients with Chagasic cardiomyopathy (Colorado et al., 2000). Additionally, the HLA-
DRB1*1503 allele was associated with genetic susceptibility to cardiac damage (Garcia 
Borras et al., 2009). All these studies were conducted with small cohorts and with different 
www.intechopen.com
 Chagasic Cardiomyopathy  
 
781 
Latin American populations. Polymorphisms of cytokine promoters assess the potential 
pattern of cytokine hypo or hyper secretion in individuals. A study showed the association 
of transforming growth factor beta (TGF1) (Calzada et al., 2009) and lymphotoxin  (LT) 
with the risk Chagasic cardiomyopathy progression (Ramasawmy et al., 2007). Tumor 
necrosis factor (TNF), a pro-inflammatory agent, is the cytokine with the strongest 
relationship to cardiac tissue damage in Chagas. There is an association between T. cruzi 
seropositive individuals and the polymorphism in TNF-238A. Indeed, TNF secretion is 
higher in non-stimulated and stimulated cells from chronic Chagasic donors (Pissetti et al., 
2011) and TNF serum levels were associated with heart failure (Talvani et al., 2004). In T. 
cruzi experimentally infected rats, the cardiomyopathy ameliorates in animals treated with a 
TNF blocking monoclonal antibody (Perez et al., 2009).  
5.2 Parasite tropisms 
Geographic distribution of an organ-specific chronic disease (cardiac versus digestive diseases) 
and allocation of T. cruzi I and II (II to VI in the new classification), supported the hypothesis 
that disease outcome is linked to the T. cruzi genetic variations. Some studies did not show 
correlations among T. cruzi lineages and the clinical forms of Chagas disease (Zafra et al., 
2011). Although, the presence of TcI was correlated with higher frequencies of 
electrocardiogram alterations than individuals infected with TcII, such as ventricular 
premature beats, first-degree atrioventricular block, sinus bradycardia, abnormal Q-waves, 
atrial fibrillation, and complex ventricular arrhythmias (Ramirez et al., 2010). In a mouse 
model infected with two different genetic populations of T. cruzi, both parasites were found 
during the acute infection in several host compartments (blood and organs). However, during 
chronic infection, a preferential tissue distribution with predominance of certain T. cruzi 
isolates was found (Andrade et al., 1999). Because T. cruzi mixed infections in triatomines are 
found in high rates, a similar phenomenon should take place during human infection. 
5.3 Parasite invasion of the host cells 
T. cruzi can reach the mammalian host cells via different mucosal tissues (i.e., conjunctiva, 
oral) or directly into blood (transfusion or congenital). The parasite in vivo can invade a vast 
range of cells such as monocyte/macrophages, dendritic cells, endothelial cells, fibroblasts, 
astrocytes, skeletal muscles, enteric nerves, and cardiomyocytes (Epting et al., 2010). Parasite 
invasion is a multistep process when several T. cruzi glycoproteins bind surface molecules 
on the host cells. Before reaching the target tissues, T. cruzi must interact with the 
endothelial cells to actively penetrate or increase endothelium vasodilatation. Parasite 
protease can produce inflammations that increase vascular permeability (Epting et al., 2010). 
Several parasite proteases and glycoprotein expressed by trypomastigotes have been 
associated with invasion: gp60 (penetrin) gp63, gp35/50, gp82, gp90 a parasite glycosidase, 
mucins and transialidase such as gp85 or Tc85. The binding of these parasite molecules to 
host molecules (cytokeratin 18, mucins, heparan sulfates, extracellular matrix proteins such 
as fibronectin and laminin, and carbohydrates with sialic acid) induce Ca++ mobilization, 
protein tyrosine phosphorylation and cytoskeleton reorganization in the target cells. 
Transialidase, glycosylphosphatidylinositol (GPI) anchors surface-bound proteins are in 
charge of transferring sialic acid residues from the host cell to the parasite glycoproteins. 
This mechanism seems to be crucial in invasion given that trypomastigotes with no 
expression of trans-sialidases were poorly invasive to non-phagocytic cells (Epting et al., 
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2010). Also, infection by oral route involved other parasite glycoproteins such as mucin-like 
gp35/50 or gp82 on the surface of the trypomastigotes, resistant to protease digestion. 
Glycoprotein gp82 binds to the gastric mucin and allows the parasite to invade epithelial 
cells (Yoshida, 2008). 
5.4 Acute and chronic heart involvement in Chagas diseases  
5.4.1 Acute myocarditis 
Parasite genetic variations, the initial parasite burden, and the host immune response seem 
to influence the evolution of the Chagas disease. Clinical cardiac involvement is found in 
nearly 90% of symptomatic patients. Parasite-infected myocardiocytes with intracellular 
amastigotes (pseudocyst) break up and induce acute inflammation (Coura & Borges-Pereira, 
2010). There is massive and diffuse infiltration with predominance of mononuclear cells 
(Fig. 3A) mainly CD8+ T lymphocytes (LT) up to 60% (Fig. 3B). Whether these LT are T. 
cruzi antigen specific and which chemotactic agents control this migration is unknown. 
Microarray studies of T. cruzi acute infection in mouse cardiomyocytes showed a regulation 
of 353 genes (111 up regulated and 242 down regulated) associated with inflammation, 
cytoskeleton, cell interaction, apoptosis, cell cycle, and oxidative stress. Interestingly, early 
genes up regulated include a vast range of chemokines, which attract mononuclear cells 
(Manque et al., 2011). In consequence, there is cell destruction (myocytolysis), interstitial 
edema, hypertrophy of myocardial fibers, and alteration of the cardiac microcirculation with 
platelet aggregation, production of pro-inflammatory cytokines and expression of vascular 
adhesion molecules by endothelial cells (Rossi et al., 2010).  
 
 
Fig. 3. Immunohistology of a heart with acute Chagas disease showing extensive cellular 
infiltration 10x (A), and presence of CD8+ (black arrow and brown cells) and CD4+ T cells 
(white arrow and red cell) with hematoxylin as contra-staining 100x (B). Courtesy of Ana M. 
Uribe, M.D. Pathology Department, School of Medicine, Pontificia Universidad Javeriana, 
Bogota D.C., Colombia. 
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5.4.2 Chronic myocarditis 
Contrary to acute infection, in the chronic phase there is scarcity of T. cruzi niches; however, 
there is an extensive, but patchy mononuclear infiltration, with predominance of 
macrophages and cytotoxic CD8+ T cells (CTL). Myocarditis has a slow progression with 
changes in the contractile function and dilatation of the heart walls. Increase in 
metalloproteinase has been described in infected cardiac tissue and associated with 
remodeling of the extracellular matrix (Gutierrez et al., 2009). Histology analysis shows 
diffuse myocarditis, myocytolysis, edema, mononuclear cellular infiltration (hallmark of the 
delayed hypersensitivity), destruction of the conduction system with neuron loss 
(autonomic denervation), and extensive myocardial fibrosis. Functional studies in Chagasic 
cardiopathy demonstrated impaired perfusion at the coronary vessels due to microvascular 
changes (thrombi, inflammation, and spam) (Rossi et al., 2010).  
5.5 Mechanisms of tissue damage 
5.5.1 Autoimmunity 
The autoimmune theory was initially based on the scarcity of parasites found in chronically 
infected tissue and also on the presence of antibodies and T cells that recognized parasite 
antigen and cross-reacted with host tissues and molecules. Antibodies against T. cruzi bind 
to human laminin, sulfo-galactosylceramides, cardiac myosin, microtubule-associated 
proteins, ribosomal proteins, ┚-adrenergic and muscarinic receptors; heart sarcolemma, 
blood vessel, neurons, glial cells, myocardium and skeletal muscles (Bonney & Engman, 
2008). However, demonstration of the pathological consequences due to autoimmunity in T. 
cruzi infection does not have direct evidence. Most of the auto-antibodies are considered to 
be natural antibodies that could be induced after tissue injury and exposure of host cell 
molecules. Also, T. cruzi antigens can act as B cell polyclonal stimulators. Against the 
autoimmunity theory it is known that the immune-suppression exacerbates T. cruzi infection 
and specific anti-parasitic treatment ameliorates the clinical disease (Rossi et al., 2010). 
5.5.2 Antigenic persistence and immune response 
By using DNA techniques, the presence of T. cruzi in tissues during chronic infection has 
become clear. Antigen persistence triggers inflammation and lymphocyte infiltration. 
Damage mechanisms are unclear because parasite burden does not explain extensive cell 
loss. CD8+ T lymphocytes contribute to cytotoxicity probably via perforin and granzyme 
B, and TGB- and interleukin-10 (IL-10) secreting macrophages can induce repair and 
fibrosis through fibroblasts. T. cruzi infection also alters microcirculation with the 
presence of platelets aggregated, microvascular spam, and secretion of vasoconstrictor 
agents such as tromboxane A2 (TXA2) and platelet activated factors (PAF) by 
macrophages or endothelin 1 (ET-1) by endothelial cells (Rossi et al., 2010).  
6. Human immune response 
Innate immune cells such as natural killer cells, macrophages, and dendritic cells detect 
invading pathogens and alert the immune system through activation cascades. The aim is to 
elicit innate antimicrobial and inflammatory responses and initiate adaptive immunity to 
control or eliminate infection. It is accepted that the establishment of chronic infection with 
T. cruzi is a consequence of the inability of the immune response to elicit sterilizing anti-
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parasite immunity. Therefore, the host innate and adaptive immune response is believed to 
be the key determinant of the clinical outcome of the disease. 
6.1 Innate immunity 
Dendritic cells (DCs), natural killer (NK) cells, and monocytes are vital mediators of the 
innate immune system and promote development of adaptive immune responses. Evidence 
shows that T. cruzi may infect DCs and even proliferate inside them. Consequently, the DC 
antigen presentation capacity is reduced (Van Overtvelt et al., 2002). In early asymptomatic 
Chagas disease, higher levels of pro-inflammatory monocytes and expansion of NK cells 
before the adaptative immunity development has been shown (Vitelli-Avelar, 2006). The 
role of cytokines such as interleukin (IL)-4, IL-12, TNF┙, and interferon (IFN) secreted by 
these cells can be an important element for host resistance during the early stages of 
infection and also in the genesis of myocarditis (Golgher et al., 2004). It has been shown that 
two different and independent antigenic stimuli from the parasite induce both an 
enhancement of IL-10 and a reduction of IL-12 secretion in DCs from Chagasic patients 
compared to DCs from healthy donors (Cuellar et al., 2008). Although, the innate immune 
system seems to have a fundamental role in Chagas disease by controlling parasite 
replication and spread in host tissues, it is not clear if events described here, that mediate 
inflammatory reaction, can be related to protection or tissue damage in the chronic phase of 
the disease.  
6.2 Humoral immune response 
A specific antibody response and B cells in animal models of Chagas disease seem to play an 
important role for parasite control, especially against the trypomastigotes. In spite of the 
large number of parasite proteins some molecules have been studied. Indeed, in our 
previous work, we showed that there is a consistently higher specific IgG response in 
chronic Chagasic patients against T. cruzi kinetoplastid membrane protein-11 (KMP-11), and 
the T. cruzi heat shock protein-70 (HSP-70). The recombinant KMP-11 protein recognition 
was focused on IgG1 sub-fraction; whereas, the lysate was on IgG3 plus IgG1 in 
asymptomatic and cardiopathic chronic phases, compared to acute sera from Chagasic 
patients (Flechas et al., 2009). These data reflect the dynamics of the humoral immune 
response in Chagas disease and may be an important issue given that IgG1 and IgG3 are the 
major complement fixing isotypes, which also mediate cooperative function with 
phagocytes; nevertheless, the role of these specific antibodies in controlling the infection or 
progressing in disease severity need to be addressed. 
6.3 T cells and cytokines 
Individuals undergoing chemotherapy generally show protection against viral infections 
controlled by T cells during lymphopenia, indicating that a small population of T cells can 
be protective (Turtle et al., 2009). However, reactivation of Chagas disease, defined by a 
demonstration of trypomastigotes on microscopic examination of blood or the identification 
of amastigotes on biopsy samples and/or acute clinical manifestations during the chronic 
phase, can occur among the immunosuppressed patients with heart transplantation (Burgos 
et al., 2010) or AIDS patients (Almeida et al., 2009). It may be the natural history disease 
demonstration that T cell response is crucial to control parasite burden and clinical 
manifestations in a large proportion of patients. Perhaps the most interesting question is 
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how adaptive immune response can contribute to most infected individuals remains 
asymptomatic whereas an important percentage of these patients develop severe forms of 
the disease. In humans, it has been shown that CD4+ T cells (Cuellar et al., 2009) and CD8+ 
T cells (Fiuza et al., 2009) from Chagasic patients specifically produced IFN after exposure 
to T. cruzi antigens. Furthermore, chronic Chagasic patients had lower levels of antigen-
specific CD8+ T cells secreting IFN compared with non-symptomatic individuals (Laucella 
et al., 2004). Because T. cruzi is an intracellular parasite, many groups have focused on the 
study of CD8+ T cells. Some of them have studied specific CD8+ T cells against peptides 
derived from cruzipain, FL-160 (Fonseca et al., 2005), KMP-11 (Diez et al., 2006; Lasso et al., 
2010), and trans-sialidases (Alvarez et al., 2008) proteins, founding similar frequency of 
specific CD8+ T cells for these epitopes. Nonetheless, it has been shown that patients with 
more severe forms of Chagas disease have more differentiated CD8+ T cells which could 
have lost their functional capacity (Bixby & Tarleton, 2008). One interesting aspect is the 
control of immune response by regulatory T cells (Treg). Ex vivo, it was shown that children 
with asymptomatic Chagas disease display a lower frequency of natural Treg CD4+ CD25high 
compared to non-infected children (Vitelli-Avelar et al., 2006). Interestingly, these cells are 
in increased levels in peripheral blood of late chronic asymptomatic patients (Vitelli-Avelar 
et al., 2005). These data suggest that Treg could be important to limiting tissue damage. 
However, taking into account that additional molecules have been suggested to identify Treg, 
we used a panel of antibodies for CD4, CD25, FoxP3, and CD127. Our results show higher 
proportion of Treg in symptomatic chronic Chagasic patients compared to non-infected 
individuals, indicating that the frequency of Treg can contribute to damage. Fig. 4 despites 
the CD4+ Treg cells by flow citometry (Lasso et al., 2009). 
 
 
Fig. 4. Regulatory T cells from chronic Chagasic patient identified by high levels of 
expression of the transcription factor forkhead box transcription factor P3 (FoxP3) and low 
levels of CD127. Courtesy of Paola Lasso, Pontificia Universidad Javeriana, Bogota D.C., 
Colombia. 
7. Diagnosis 
The diagnosis of Chagas disease, as with other infections, is performed on the basis of 
clinical findings, parasite presence, serological status, and epidemiological data. 
Furthermore, the disease stage is also an important fact to consider. For instance, as the 
parasitemia dramatically decreases from acute to chronic phase, in the early phase parasite 
detection is achieved by parasitological conventional direct tests (see below). Nevertheless, 
because clinical findings in this stage can be confused with other pathologies, the 
epidemiological data demonstrating a connection between the patient and the parasite is of 
special importance (Nicholls et al., 2007). In contrast, in chronic patients, the presence of 
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symptoms or abnormal clinical findings usually correlates with the disease but parasite 
concentration is low and variable. Bearing in mind that T. cruzi infection is life lasting; in the 
chronic phase serological tests are applied to indirectly demonstrate parasite presence 
(Enciso et al., 2004). Indeed, the WHO recommends that to diagnose a chronic Chagasic 
patient; besides having clinical findings compatible with Chagas disease and history of 
vector contact, there must be at least two positive serological tests with different 
immunological principles. Finally, chronic asymptomatic patients represent a real challenge 
for diagnosing inasmuch as there are no clinical findings, and again parasitemia is very low 
and intermittent. Consequently, the epidemiological patient history is also of most 
importance (Gil et al., 2007). 
7.1 Clinical findings  
7.1.1 Electrocardiogram 
The most common electrocardiographic manifestations are right bundle branch block 
(RBBB), anterior fascicular block, premature ventricular contractions, changes in ST segment 
and T wave, abnormal Q waves, and low voltage of the QRS complex (Fig. 5). The 
combination of the RBBB and the anterior fascicular block suggest the disease (Garzón et al., 
1995). The presence of frequent premature ventricular contractions, including duplets and 
salvos of non-sustained ventricular tachycardia are a common finding in the Holter 
monitoring and in the stress test. Premature ventricular contractions correlate with the 
severity of the ventricular function, but can also occur in patients with preserved ventricular 
function. Episodes of non-sustained ventricular tachycardia are observed in 40% of the 
patients with light to moderate ventricular contractibility alterations and in virtually all 
patients with heart failure, which is more frequent than in other cardiomyopathies. 
Sustained ventricular tachycardia is another disease marker. This arrhythmia can be 
produced through programmed ventricular stimulation in nearly 85% of the cases and 
results from intramyocardial or subepicardial reentrant phenomena, usually located on the 
inferoposterior and lateral wall of the left ventricle. 
7.1.2 X-ray and echocardiography 
In patients in the undetermined phase, the cardiac silhouette evaluated in the chest X-ray 
and the global systolic function in echocardiography are normal. In more advanced stages, 
the chest X-ray can show cardiomegaly and pulmonary congestion. The disease can cause 
diffuse damage of the systolic function of the left ventricle. The global systolic function of 
the left ventricle has prognostic implications. In a cohort of 538 patients grouped into four 
stages of disease progression, different survival rates were found in the five-year follow up 
from 98%, 91%, 45% to 13% for those with normal left ventricle function, moderately 
depressed function, with reversible heart failure, or irreversible heart failure, respectively 
(Rassi et al., 2010). Some alterations of the segmental contraction of the left ventricle can be 
detected. The most common is located on the posterior wall with 20% prevalence. The 
presence of mitral or tricuspid insufficiency is generally associated to ring expansion. The 
prevalence of aneurysms in the left ventricle varies in the different series, noted on an 
average of 8.5% in asymptomatic individuals and in patients with severe cardiac damage up 
to 55%. Through logistic regression analysis, the presence of an apical aneurysm in the left 
ventricle was an independent predictor of mural Thrombi (Albanesi-Filho et al., 1991). In 
another work, the finding of an aneurysm was significantly associated to a thrombus and 
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cerebro-vascular accident during a two-year follow up. On some instances, diminished 
systolic function of the right ventricle can be the only abnormality detected via 
echocardiography; in general, it is secondary to the severity to the damage of the left 
ventricle and at high levels of pulmonary pressure. With regards to diastolic function, 
chronic myocarditis in Chagas disease can diminish ventricular relaxation and diastolic 
filling. These abnormalities usually precede systolic dysfunction. Reduced compliance of the 
left ventricle can increase the filling pressure of the left atrium with changes in transmitral 
and pulmonary venous flow rates. The echocardiography study is recommended as a 
routine clinical evaluation method in patients with Chagas cardiopathy to determine the 
stage of the disease, its progression, as well as to estimate survival, dismiss the presence of 
aneurysms or intracavitary thrombi, and monitor response to treatment. 
 
 
Fig. 5. ECG sequence in a 72-year-old woman diagnosed with Chagas cardiomyopathy and 
ejection fraction of the left ventricle at 25%. Note sinus bradycardia (A), attrial fibrillation 
(B), and monomorphic sustained ventricular tachycardia (C). Fundación Clínica Abood 
Shaio, Bogota D.C., Colombia. 
In our experience at Fundación Clínica Abood Sahio (Bogotá, Colombia), from a total of 120 
patients evaluated with diagnosis of Chagas cardiomyopathy, 73 women (60%) with mean 
age of 56.7 +/- 13 years (21-84), clinical manifestations corresponded to dyspnea (42%), 
palpitations (31%), chest pain (42%), presyncope (24%), syncope (27%), and aborted sudden 
death (2.5%). Nearly 6.7% of the cases did not present clinical manifestations. The main ECG 
findings were: right bundle branch block (40%), second and third degree AV block (29.2%), 
dysfunction of the sinus node (28.3%), ventricular tachycardia (23%), atrial fibrillation (19%), 
left anterior hemiblock (17.2%), atrial flutter (3.3%), and left bundle branch block (3.3%). In 
31% of the cases, the chest X-ray was normal. In 15.8%, severe cardiomegaly was observed. 
All the patients were subjected to a color Doppler echocardiogram according to 
internationally recognized norms, finding a mean fraction of the left ventricle of 43.3% (SD 
+/- 16.5) (10-60) and of the right ventricle at 23.4% (10-40) (Fig. 6). The study was considered 
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normal in 33.6% of the cases. Contractility alterations were documented in 42.4%, with these 
being globally in 26.5% of the cases, or inferior, apical-inferior and anterior localization. 
Isolated compromise of the right ventricle was observed in one case (0.8%), suggesting the 
diagnosis of arrhythmogenic dysplasia of the right ventricle. In 24% of the cases mitral 
insufficiency was evidenced and 15.2% revealed tricuspid insufficiency. A total of 11 
aneurysms (9.7%) were observed, 63.6% of apical localization and 36.3% of inferior 
localization. Some 8.8% of the patients presented intracavitary thrombi, generally related to 
aneurysms or global contractility alterations. Holter or electrophysiological study 
documented ventricular tachycardia (sustained or unsustained) in 19.4% of the cases. 
Additionally in 10% we observed association to sinus dysfunction and/or AV block with 
ventricular tachycardia. Anatomic-pathological findings obtained via biopsy or surgery in 
10 Chagas patients were: a) hypertrophy and/or b) fibrosis and/or c) chronic inflammatory 
infiltrate. None of the cases reported parasites in the samples examined by pathology (Rosas 
et al., 2007). 
 
 
Fig. 6. Echocardiography M mode (A) and bi-dimensional (B) of 54-year-old female with a 
history of aborted sudden death due to ventricular tachycardia) secondary to Chagasic 
cardiomyopathy. Note the severe dilatation of right ventricle. Fundación Clínica Abood 
Shaio, Bogota D.C., Colombia. 
7.2 Laboratory tests 
7.2.1 Conventional parasitological tests 
These can be classified into direct and indirect tests. Direct methods, employed basically in 
the acute phase, include parasite microscope-observation in blood fresh preparation which 
permits to observe parasite movement. On the contrary, thin or thick blood smears stained 
with Giemsa led to a better morphological identification, which is of special importance in 
areas where Trypanosoma rangeli also circulates. Importantly, parasite concentration methods 
like blood centrifugation, Strout method, and microhematocrit increase the probability of 
trypomastigote detection. Because of their great time consumption, indirect parasitological 
methods are generally used to diagnose patients in the chronic phase. They refer to 
hemoculture and xenodiagnosis (Luquetti, 2007). 
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7.2.2 Serological tests  
There is a broad spectrum of serological tests, whose final goal is to detect anti-T. cruzi 
antibodies, usually of the IgG isotype in the chronic phase or IgM in the acute phase. The 
tests most used, called conventional tests for serological Chagas disease diagnosis, are the 
indirect immunofluorescence test (IFAT), the enzyme-linked immunoabsorbent assay 
(ELISA), and the indirect haemaglutination test (IHA). Generally, the antigens used are 
parasite lysates or mixtures of parasite recombinant proteins. Due to the huge parasite 
polymorphisms (Rodríguez et al., 2002), it is recommended to use isolates circulating in the 
specific endemic area or mixture of them.The applied method must be carefully 
standardized and validated in inter-laboratory international and national tests. Most of the 
above-mentioned tests can detect the infection in more than 95% of sera. Nevertheless, false-
positive reactions can occur in T. rangeli or Lesihmania-infected patients, as well as false-
negative in the case of recently-infected chronic patients or immunosuppressed patients (Gil 
et al., 2007; Luquetti, 2007). 
7.2.3 PCR 
PCR tests, because of their power of detection and specificity, constitute a complementary 
diagnostic method for detecting T. cruzi in diverse biological samples. They are of especial 
interest with chronic patients because of their higher sensitivity compared with 
conventional parasitological tests. There are several PCR tests available for detecting T. 
cruzi. Their performance varies depending on aspects like type and number of the target 
amplification, lack of polymorphisms among the parasite DTU-annealing primer target, 
sample volume, treatment and conservation, DNA extraction method, type of DNA 
polymerase used, and thermo-cycling program, among variables (Schijman et al., 2011). 
Some PCR tests show disadvantages like the amplification of polymorphic fragments or of 
similar-size bands in both T. cruzi and T. rangeli infections, the deviation of the test towards 
T. cruzi in mixed infections with T. rangeli, and the possible integration of the parasite’s 
kDNA in the human genome (Gil et al., 2007; Pavía et al., 2003, 2007). Bearing all this in 
mind, the Molecular Parasitology Laboratory at Pontificia Universidad Javeriana designed 
and standardized the TcH2AF-R PCR, specific for T. cruzi (Pavia et al., 2003). This PCR 
amplifies the 16-255 nucleotides of the T. cruzi SIRE repetitive element and does not present 
amplification signal in T. rangeli. Assays on triatomine vectors experimentally and naturally 
infected with T. cruzi revealed that TcH2AF-R PCR allows identifying the parasite in all the 
infected specimens, with performance equal to that of S35/S36 PCR, considered among the 
most sensitive PCR tests for T. cruzi identification (Pavia et al., 2007). Likewise, in blood 
samples from Chagasic patients, it was observed that of 156 samples, 84 (53.8%) were 
positive with both TcH2AF-R and S35/S36 PCRs, while 89 (57%) were positive for indirect 
immunofluorescence (IIF) and enzymatic immunoassay (ELISA) (Gil et al., 2007). A study of 
the performance of the TcH2AF-R and S35-S36 primers in cardiac tissue of mice infected 
with T. cruzi I showed that by using both pairs of primers it is possible to detect the parasite 
in the acute and chronic stages of the infection, with performance above that of the micro-
hematocrit and eliminate of the histopathological analysis (Barrera et al., 2008). Recently, by 
combining TcH2AF-R and S35/S36 PCRs, it was possible to follow up a Colombian heart 
transplant in a Chagasic patient, as well as the first Colombian congenital case (Pavia et al., 
2009, 2011). Because of its higher sensitivity, a few real time PCR (qPCR) methods have been 
developed to monitor drug efficacy and Chagas disease reactivation in transplanted 
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Chagasic patients. However, international studies to evaluate PCR methods for parasite 
DNA detection in blood samples as that launched by Shijman et al., (2011) are urgently 
needed. 
7.3 Epidemiological context 
Epidemiological data, such as that shown in Table 2, seek to determine if the patient could 
have been in contact with the parasite. 
 
Epidemiological data Information included 
Born in endemic areas Housing conditions like thatched roof, dirt floors, 
adobe walls, etc. 
Presence of domestic animals. 
Rural, peri-domestic, or domestic dwellings 
Time of living in relationship to already performed 
vector control campaigns in the area (important in 
congenital transmission) 
Living in endemic areas 
Visits to endemic areas 
Vector knowledge Awareness of vectors circulating in the specific area 
Chagasic relatives  Parents, siblings, or any family member infected 
Work activity 
Important in accidental transmission in both 
endemic and non-endemic areas 
History of blood transfusions Amount and place 
History of organ transplant Medical and epidemiological history of the donor 
Table 2. Epidemiological data supporting risk of T. cruzi infection 
8. Treatment  
8.1 Symptomatic 
In the absence of random clinical studies in patients with Chagas disease and heart failure, 
traditionally the recommendations have been extrapolated from the management guides for 
heart failure from other causes (Jessup et al., 2009). However, it should be noted that in the 
physiopathology of the Chagas disease there are clinical and therapeutic peculiarities with 
important implications. For example, high doses of diuretics are necessary in advanced 
stages of the disease due to predominance of the systemic congestion manifestations over 
signs of pulmonary congestion. In patients with Chagas cardiopathy, conduction 
disturbances are also frequent, which may be aggravated by the use of Digoxin, 
Amiodarone, and specially Beta-blockers (Marin-Neto et al., 2010). Cardiac re-
synchronization is a treatment alternative for patients with heart failure, especially in the 
presence of left bundle branch block. However, its usefulness in patients with right bundle 
branch block common in Chagas disease has not been shown as patients with another type 
of pathology in the presence of this conduction alteration. Other palliative procedures like 
dynamic cardiomyoplasty and partial left ventriluculotomy are contraindicated because of 
unsatisfactory results. Heart transplant is an option indicated in patients selected in final 
stages of cardiac insufficiency. In these cases, it must be highlighted that the 
immunosuppressant therapy indicated to avoid transplant rejection may induce reactivation 
of the T. cruzi infection (Campos et al., 2008). Under certain circumstances, reducing the 
dosage of immunosuppression is recommended, as well as starting etiological treatment in 
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cases of reactivation (Fiorelli et al., 2005). The potential benefit of transplanting stem cells in 
patients with Chagasic cardiopathy is under evaluation (Tura et al., 2007). Because of the 
high frequency of thrombus-embolic phenomena, anticoagulation is indicated in patients 
with atrial fibrillation, in the prior embolism, in the presence of aneurysms or thrombi, and 
in cases of heart failure in advanced stages even in the absence of random controlled studies 
that prove its efficacy. Some observational data suggest that Amiodarone can improve 
survival in patients with Chagas disease with risk of sudden death due to malignant 
arrhythmia (Garguichevich et al., 1995). For this reason, Amiodarone is usually 
recommended in patients with sustained ventricular tachycardia and in cases of 
unsustained ventricular tachycardia associated to ventricular systolic dysfunction (Leite et 
al., 2003). Patients with sustained ventricular tachycardia with hemodynamic instability and 
in cases of aborted sudden death, the implant of a cardio-defibrillator is recommended 
(Rassi et al., 2009). Radiofrequency ablation is an alternative in patients with ventricular 
tachycardia (D´Avila et al., 2002); however, its impact on survival and recurrence of the 
arrhythmia is yet to be established. The finding of severe bradyarrhythmias like those 
observed in the complete AV block and in the sinus dysfunction must be treated by 
implanting a definitive pacemaker as in other cardiac conditions (Epstein et al., 2008). The 
benefit of the pacemaker implant in patients with Chagasic cardiopathy is mainly based on 
reports of case series. 
8.2 Etiological 
The only medications currently used with Chagas disease due to ethical and efficiency 
reasons are Nifurtimox and Benznidazole (Bern et al., 2007). Based on the literature review, 
the recommendations of the antitrypanocidal therapy vary according to the phase and form 
of the Chagas disease, the patient’s age, and the severity of the disease. The pharmacological 
therapy is recommended in all acute and congenital cases, in infection by reactivation, in 
patients up to 18 years of age, and in children. For adults between 19 and 50 years of age 
and without advanced cardiopathy, the treatment can be offered (Bern et al., 2007). In 
individuals above 50 years of age, risk of toxicity from the drug may be higher than in 
young adults and the treatment is considered optional. Once the diagnosis has been 
confirmed through corresponding serological tests, patients must be evaluated with a 
clinical history and a careful physical exam. Additionally, in all cases, an electrocardiogram 
should be performed. With asymptomatic individuals without electrocardiographic 
alterations, the prognosis tends to be favorable and it is recommended that these patients be 
monitored every 12 to 24 months. Patients with electrocardiographic changes consistent 
with the disease’s cardiovascular compromise should be evaluated via thoracic X-ray and 
echocardiogram that permit defining the ventricular size and function, as well as other types 
of structural alterations and via 24-h electrocardiographic monitoring or Holter test to detect 
arrhythmias.  
9. Prognosis 
The prognosis of some diseases like Chagas has not been easy to establish because of the 
great differences in their clinical course among the affected countries. Results like the survey 
by Maguire et al., (1987) showed that from 20-59 years of age, the risk was strongly related 
to electrocardiography status. Indeed, patients with ventricular conduction defects have 
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higher mortality rates than infected patients without electrocardiographic abnormalities. 
Also, it was observed that abnormal diastolic function is related to severe myocardial 
damage (Rocha et al., 2009). Another survey found that there are six prognostic factors of 
disease development: NYHA class III or IV, cardiomegaly on chest radiography, segmental 
or global wall motion abnormalities on echocardiography, non-sustained ventricular 
tachycardia on Holter monitoring, low QRS voltage on electrocardiography, and male sex 
(Rassi et al., 2006). Recent studies have found that there are four echocardiographic 
variables associated with the disease outcome: left ventricular ejection fraction, right 
ventricular function, E/E’ ratio, and left atrium volume (Rocha et al., 2009). Finally, the 
prognosis of the patient will rest on the good care and follow up of the caregivers. Chagas 
disease is no longer a disease of the poor; it is now a disease of any country with important 
socioeconomic impact.  
10. Conclusions 
Prediction markers for disease development, and progression, immunotherapy and vaccine 
strategies, new anti-T. cruzi drugs, and world-standardized PCR tests, are urgently required 
to improve early diagnosis and treatment of this worldwide health problem. Government, 
health organizations, and scientists all over the world need to come together to construct 
policies and strategies to prevent and control this silent but devastating disease in endemic 
and non endemic countries.  
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